Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1987-07-08
1992-01-14
Moskowitz, Margaret
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
43524027, 424 858, C07K 1528, C12N 520, A61K 39395
Patent
active
050812300
ABSTRACT:
Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein. The antibodies are secreted by hybridomas obtained by immunizing mice with the Ha ras p21 protein containing the arginine mutation at position 12 of the protein. The antibodies and immunoreactive fragments thereof of useful for detection, diagnosis, quantitation, staging and classification of normal and activated ras p21s in normal tissues, malignant and premalignant lesions.
REFERENCES:
patent: 4535058 (1985-08-01), Weinberg et al.
patent: 4568640 (1986-02-01), Rubin
patent: 4699877 (1987-10-01), Cline et al.
patent: 4725550 (1988-02-01), Perucho et al.
patent: 4762706 (1988-08-01), McCormick et al.
patent: 4786718 (1988-11-01), Weinberg et al.
patent: 4820631 (1989-04-01), Lacal et al.
patent: 4871838 (1989-10-01), Bos et al.
Andreeff et al., Blood pp. 676-681, vol. 67, No. 3, Mar. 1986.
Barch et al., Cell Biology, Abstract #591, St. Louis, Mo. (1987).
Bizub et al., Oncogene, pp. 131-142, vol. 1, 1987.
CA 106;174296y, p. 550, vol. 106 (1987).
Carney et al., 78th Annual Mtg. of Amer. Assoc. for Cancer Research, May 20-23, 1987.
Carney et al., UCLA Symposia, Jan. 20-Feb. 15, 1986, Steamboat Springs Co; Alan N. Liss, Inc., N.Y. Journal of Cellular Biochemistry Suppl. 10A (1986).
Carney et al., 5th Annual Congress for Hybridoma Research, Jan. 26-29, 1986, Balt., Md.
Carney et al., Lab. Invest. 54-10A, Jan. 1986.
Carney et al., J. Cell. Bio. pp. 207-214, vol. 32 (1986).
Carney et al., Int'l., Academy of Pathology, Mar. 1987.
Carney et al., Third Annual Mtg on Oncogenes, 1987.
Carney et al., Monoclonal Antibodies & Cancer Therapy, pp. 565-572 (1985).
Carney et al., UCLA Symp. Mol. Cell. Biol., New Ser., pp. 565-572, vol. 27 (1985), CAS vol. 104 (1986), No. 166570B.
Caruso et al., Int. J. Cancer, pp. 587-595, vol. 38 (1986).
Chang et al., Nature, pp. 479-483, vol. 297, Jun. 10, 1982.
Carney et al., 69th Annual Mtg. of Federation of American Societies for Experimental Biology (FASEB), Apr. 1985.
Carney et al., Apr. 1986 Mtg of FASEB.
Carney et al., PNAS (U.S.A.), pp. 7485-7489, vol. 83, Oct. 1986.
Ward et al., "Comparative Immunohistochemical Reactivity of Monoclonal and Polyclonal Antibodies to H-ras p21 in Normal and Neoplastic Tissues of Rodents and Humans". Oncogene 4:203-213 (1989).
Sorrentino et al., "Preparation, Characterization, and Properties of Monoclonal Antibodies Against Intact H-ras p21 Proteins" Oncogene 4:215-221 (1989).
Hamer et al., "Production and Characterization of Anti-Ras p21 Monoclonal Antibodies", Draft Tentatively Accepted by Hybridoma, to be Published.
Furth et al., "Monoclonal Antibodies to the p21 Products of the Transforming Gene of Harvey Murine Sacroma Virus and of the Cellular ras Gene Family", pp. 294-304, Jul. 1982, vol. 43, No. 1, of Virology.
Hand et al., "Monoclonal Antibodies of Predefined Specificity Detect Activated ras Gene Expression in Human Mammary and Colon Carcinomas", pp. 5227-5231, Aug. 1984, vol. 81, PNAS.
Taparowsky et al., Banbury Report, 14:123-133 (1983), cited in Chem. Abstracts, CA 100(1):1425n.
Shimizu et al., Nature, 304(5926), 497-500 (1983), cited in Chem. Abstracts, 99(19):15309b.
Fasano et al. J. Mol. Appl. Genet., 2(2):173-180 (1983), cited in Chem. Abstracts, CA 99(19)153080v.
Tanaka et al., "Efficient Generation of Antibodies to Oncoproteins by Using Snythetic Peptide Antigens", pp. 3400-3404, May 1985, vol. 82, PNAS USA.
Tabin et al., "Mechanism of Activation of a Human Oncogene", pp. 143-149, Nov. 11, 1982, vol. 300, Nature.
Reddy et al., "A Point Mutation is Responsible for the Acquisition of Transforming Properties by T24 Human Bladder Carcinoma Oncogene", pp. 149-152, Nov. 11, 1982, vol. 300, Nature.
Yuasa et al., "Acquisition of Transforming Properties by Alternative Point Mutations with c-bas/has Human Proto-Oncogene", pp. 775-779, Jun. 30, 1983, vol. 303, Nature.
Bos et al., "Amino-Acid Substitutions at Codon 13 of the N-ras Oncogene in Human Acute Myeloid Leukaemia", pp. 726-730, Jun. 27, 1985, vol. 315, Nature.
Wong et al., "Detection of Activated M.sub.r 21,000 Protein, the Product of ras Oncogenes, Using Antibodies with Specificity for Amino Acid 12", pp. 6029-6033, Dec. 1986.
Clanton et al., Mol. Cell. Biol. pp 3092-3097, vol. 7, No. 9, 1982.
Clark et al., PNAS (USA), pp. 5280-5284, vol. 82, No. 16, Aug. 1985.
Cooper et al., Biochimica et Biophysica Acta, pp. 9-20, vol. 738 (1984).
DeLellis et al., Intl. Academy of Pathology, Mar. 1987.
Der et al., Cell., pp. 167-176, vol. 44, Jan. 17, 1986.
Feramisco et al., Nature (England) 314 (6012):639-642, Apr. 18-24, 1985.
Finkel et al., Cell., pp. 151-158, vol. 37, May 1984.
Freedman et al., In Vitro Cellular Developmental Biology, pp. 621-624, vol. 22, No. 10, Oct. 1986.
Gallick et al., PNAS, pp. 1795-1799, vol. 82, Mar. 1985.
Gambke et al., Nature, pp. 476-478, vol. 307, Feb. 2, 1984.
Ghosh et al., J. Clin. Pathol. (England), pp. 428-434, vol. 39, No. 4, Apr. 1986.
Gibbs et al., PNAS (USA), pp. 5704-5708, vol. 81, Sep. 1984.
Hamer et al, Amer. Commercial & Industrial Conference & Expo. in Biotechnology, Apr. 27-May 1, 1986, Boston, Mass.
Herlyn et al., J. Clin. Immunology, pp. 135-140, vol. 2, No. 2 (1982).
Hirai et al., Nature, pp. 430-432, vol. 327, Jun. 4, 1987.
Ho et al., FASEB, vol. 46(3), 1987.
Kuzrock et al., Cancer Research, pp. 1530-1534, vol. 46, Mar. 1986.
Lacal et al., Mol. Cell Biol., vol. 6, No. 4, pp. 1002-1009, Apr. 1986.
Lee et al., Intl. Academy of Pathology, Mar. 1987.
Lefebvre et al., Lab. Invest, 54:35a, Jan. 1986.
Liu et al., Nature, pp. 186-188, vol. 330, Nov. 12, 1987.
Manne et al., PNAS (U.S.A.), pp. 376-380, vol. 82, Jan. 1985.
McGrath et al., Nature, pp. 644-649, vol. 310, Aug. 1984.
Metzgar et al., Cancer Research, pp. 601-608, vol. 42, Feb. 1982.
Moore et al., Nature, pp. 733-734, vol. 327, Jun. 25, 1987.
Niman et al., Clin. Lab. Med. (U.S.) 6(1):181-196, Mar. 1986.
Niman et al., Proc. Natl. Acad Sci. U.S.A., vol. 82, pp. 7924-7928, Dec. 1985.
Nishida et al., Biochem. Biophys. Res. Common. 146(1):247-252 (1987).
Nitta et al., Jpn. J. Cancer Research (Gann) pp. 21-26, vol. 78, Jan. 1987.
Ohuchi et al., Can. Res. 47(5):1413-1420 (1987).
Papageorge et al., J. Virol., pp. 509-519, vol. 44, No. 2, Nov. 1982.
Parada et al., Nature, pp. 474-476, vol. 297, Jun. 10, 1982.
Poe et al., J. Biol. Chem., pp. 3906-3909, vol. 260, No. 7, Apr. 10, 1985.
Radosevitch et al., Amer. Fed. Clin. Res., Chicago, Ill., Sep. 1987.
Robinson et al., Br. J. Cancer, pp. 877-883, vol. 54, 1986.
Santos et al., Science, pp. 661-664, vol. 223, Feb. 17, 1984.
Santos et al., Nature, pp. 343-344, vol. 298, Jul. 22, 1982.
Schlom, cited in the 5th Annual Congress for Hybridoma Research, pp. 165-166, Balt., Md., Jan. 26-29, 1986.
Scolnick et al., PNAS (U.S.A.), pp. 5355-5359, vol. 76, Oct. 1979.
Sevier et al., Clin. Chem., pp. 1797-1806, vol. 27, No. 11 (1981).
Shilo et al., Nature, pp. 607-609, vol. 289, Feb. 12, 1981.
Srivastava et al., Mol. Cell. Biol., pp. 3316-3319, vol. 5, No. 22, Nov. 1985.
Sweet et al., Nature, pp. 273-275, vol. 311, Sep. 1984.
Tahara et al., Jpn. J. Can. Res., pp. 517-522, 1986.
Tanaka et al., Can Res., pp. 1465-1470, vol. 46, Mar. 1986.
Thor et al., Nature, pp. 562-565, vol. 311, Oct. 11, 1984.
Trumpe et al., Third Ann. Mtg. on Oncogenes, 1987.
Wodnar-Felipowicz et al., Orcogene, pp. 457-461, vol. 1, No. 4 (1987).
Wolfe et al., Lab. Invest., 52:77a (1985).
Zarbl et al., Nature, pp. 382-385, vol. 315, May 30, 1985.
Taparowsky et al., Cell., pp. 581-586, vol. 34 (1983).
Bernstein Denise
E. I. DuPont DeNemours and Company
Moskowitz Margaret
LandOfFree
Monoclonal antibodies reactive with normal and oncogenic forms o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies reactive with normal and oncogenic forms o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies reactive with normal and oncogenic forms o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-542545